#07137: Ginko biloba (EGb 761) protection against HIV-associated neurological diseases
………………………………………………………………………………………………………………
TECH FIELD(S)
Medical-Therapeutic
………………………………………………………………………………………………………………
FEATURES
HIV-1 Tat protein is an important pathogenic factor in HIV-associated neuropathogenesis although there are few therapies that have been developed to specifically target HIV infection in the brain. Researchers at Indiana University have discovered that a standardized formulation of Ginkgo biloba extract (EGb-761) possesses neuroprotective properties useful to prevent neurological damage of the type associated with HIV infections. A component of EGb-761, the bilobade terpene, was shown to possess the important neuroprotective properties.
EGb-761 was also found to cause down modulation of GFAP in a mouse model of AIDS neuropathology, resulting in reduced neurological impairment. In addition, GFAP levels were found to be an indication of the progression and effectiveness of treatment of HIV-associated neuropathogensis.
………………………………………………………………………………………………………………
BENEFITS
Ginko biloba extract is safe and has displayed good tolerance with no adverse drug interactions
Ginko biloba extract, and specifically the terpene bilobalide, protects against HIV-associated neuropathogenesis
GFAP represents a new biomarker for progression and treatment of HIV-associated neuropathogenesis
………………………………………………………………………………………………………………
INVENTOR(S)
Johnny J. He, Ph.D.
………………………………………………………………………………………………………………
INTELLECTUAL PROPERTY STATUS
US Provisional Patent Application
………………………………………………………………………………………………………………
CONTACT INFORMATION
For additional information on this technology, please contact Rebecca Lyon, Ph.D., Associate Director of Life Sciences, IURTC:
Indiana University Research & Technology Corporation
351 West 10th Street
Indianapolis, IN 46202
Telephone: 317.278.1916
Fax:(317) 274-5902
rlyon@iu.edu
………………………………………………………………………………………………………………
Still have a question? Ask here!